Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration

Antimicrobial Agents and Chemotherapy

Volumn 48, Issue 6, 2004, Pages 2166-2172

  Walsh, Thomas J ^a   Karlsson, Mats O ^c   Driscoll, Timothy ^d   Arguedas, Adriano G ^e   Adamson, Peter ^b,f   Saez Llorens, Xavier ^g   Vora, Ajay J ^h   Arrieta, Antonio C ^j   Blumer, Jeffrey ^b,k   Lutsar, Irja ⁱ   Milligan, Peter ⁱ   Wood, Nolan ⁱ  

^a NATIONAL CANCER INSTITUTE   (United States)

^b EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^c UPPSALA UNIVERSITY   (Sweden)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e National Children's Hospital   (Costa Rica)

^f CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^g Hospital del Nino   (Panama)

^h SHEFFIELD CHILDREN S HOSPITAL   (United Kingdom)

ⁱ PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^j CHILDREN S HOSPITAL OF ORANGE COUNTY   (United States)

^k UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C19; VORICONAZOLE;

ABDOMINAL PAIN; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; BODY WEIGHT; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONJUNCTIVITIS; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; COVARIANCE; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG ELIMINATION; DRUG EXPOSURE; DRUG FORMULATION; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; EYE PAIN; FEVER; FLUSHING; GENOTYPE; GINGIVA HYPERPLASIA; HUMAN; HYPERTENSION; IMMUNE DEFICIENCY; LIVER TOXICITY; LOADING TEST; MULTICENTER STUDY; MULTIPLE DRUG DOSE; PHARMACOKINETICS; PHLEBITIS; PHOTOPHOBIA; POPULATION PHARMACOKINETIC MODELING; PRIORITY JOURNAL; PRURITUS; SIDE EFFECT; SINGLE DRUG DOSE; STATISTICAL MODEL; STRABISMUS; STRUCTURAL PHARMACOKINETIC; SUBDURAL HEMATOMA; VISUAL DISORDER; VISUAL IMPAIRMENT;

AGING; ALLELES; ANTIFUNGAL AGENTS; BODY WEIGHT; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; GENOTYPE; HUMANS; IMMUNOCOMPROMISED HOST; INJECTIONS, INTRAVENOUS; LIVER FUNCTION TESTS; MALE; MODELS, BIOLOGICAL; PYRIMIDINES; TRIAZOLES;

EID: 2542443542     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.48.6.2166-2172.2004     Document Type: Article

References (20)

1. Ally, R., D. Schurmann, W. Kreisel, G. Carosi, K. Aguirrebengoa, B. Dupont, M. Hodges, P. Troke, A. J. Romero, and the Esophageal Candidiasis Study Group. 2001. A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin. Infect. Dis. 33:1447-1454.
2. Andes, D., K. Marchillo, T. Stamstad, and R. Conklin. 2003. In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model. Antimicrob. Agents Chemother. 47:3165-3169.
3. Beal, S. L., L. B. Sheiner, et al. (ed.). 1992. NONMEM users guides. University of California at San Francisco, San Francisco, Calif.
4. Chiou, C. C., A. H. Groll, and T. J. Walsh. 2000. New drugs and novel targets for treatment of invasive fungal infections in patients with cancer. Oncologist 5:120-135.
5. Denning, D. W., P. Ribaud, N. Milpied, D. Caillot, R. Herbrecht, E. Thiel, A. Haas, M. Ruhnke, and H. Lode, 2002. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin. Infect. Dis. 34:563-571.
6. Ghannoum, M. A., and M. A. Hossain. 2000. New investigational antifungal agents for treating invasive fungal infections. Expert Opin. Investig. Drugs 9:1797-1813.
7. Goldstein, J. A., and S. M. F. de Morais. 1994. Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 4:285-299.
8. Groll, A. H., M. Kurz, W. Schneider, V. Witt, H. Schmidt, M. Schneider, and D. Schwabe. 1999. Five-year survey of invasive aspergillosis in a pediatric cancer centre. Epidemiology, management and long-term survival. Mycoses 42:431-442.
9. Herbrecht, R., D. W. Denning, T. F. Patterson, J. E. Bennett, R. E. Greene, J. W. Oestmann, W. V. Kern, K. A. Marr, P. Ribaud, O. Lortholary, R. Sylvester, R. H. Rubin, J. R. Wingard, P. Stark, C. Durand, D. Caillot, E. Thiel, P. H. Chandrasekar, M. R. Hodges, H. T. Schlamm, P. F. Troke, B. de Pauw, et al. 2002. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N. Engl. J. Med. 347:408-415.
10. Jonsson, E. N., and M. O. Karlsson. 1999. Xpose - an SPLUS based population pharmacokinetic-pharmacodynamic model building aid for NONMEM. Comput. Methods Programs Biomed. 58:51-64.
11. Lazarus, H. M., J. L. Blumer, S. Yanovich, H. Schlamm, and A. Romero. 2002. Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study. J. Clin. Pharmacol. 42:395-402.
12. Sheehan, D. J., C. A. Hitchcock, and C. M. Sibley. 1999. Current and emerging azole antifungal agents. Clin. Microbiol. Rev. 12:40-79.
13. Shetty, D., N. Giri, C. E. Gonzalez, P. A. Pizzo, and T. J. Walsh. 1997. Invasive aspergillosis in human immunodeficiency virus-infected children. Pediatr. Infect. Dis. J. 16:216-221.
14. Sitbon, G. and A.-C. Syvänen. 2001. Multiplex fluorescent minisequencing applied to the typing of genes encoding drug-metabolizing enzymes, p. 191-200. In W. Kalow, U. A. Meyer, and R. F. Tyndale (ed.), Pharmacogenomics. Drugs and the pharmaceutical sciences. Marcel Dekker, New York, N.Y.
15. Stopher, D. A., and R. Gage. 1997. Determination of a new antifungal agent, voriconazole, by multidimensional high-performance liquid chromatography with direct plasma injection onto a size-exclusion column. J. Chromatogr. 691:441-448.
16. Venables, W. N., and B. D. Ripley. 1999. Modern applied statistics with S-PLUS, 3rd ed. Springer Verlag, New York, N.Y.
17. Walsh, T. J., C. Gonzalez, C. A. Lyman, S. Chanock, and P. A. Pizzo. 1995. Invasive fungal infections in children: recent advances in diagnosis and treatment. Adv. Pediatr. Infect. Dis. 11:187-290.
18. Walsh, T. J., I. Lutsar, T. Driscoll, B. DuPont, M. Roden, P. Gharamani, M. Hodges, A. H. Groll, and J. R. Perfect. 2002. Voriconazole in the treatment of aspergillosis, scedosporiosis, and other invasive fungal infections in children. Pediatr. Infect. Dis. J. 21:240-248.
19. Walsh, T. J., P. Pappas, D. J. Winston, H. M. Lazarus, F. Petersen, J. Raffalli, S. Yanovich, P. Stiff, R. Greenberg, G. Donowitz, J. Lee, M. Schuster, A. Reboli, J. Wingard, C. Arndt, J. Reinhardt, S. Hadley, R. Finberg, M. Laverdiere, J. Perfect, G. Garber, G. Fioritoni, and E. Anaissie. 2002. Voriconazole versus liposomal amphotericin B for empirical antifungal therapy in persistently febrile neutropenic patients: a prospective, randomized, multicenter, international trial. N. Engl. J. Med. 346:225-234.
20. Winkelstein, J. A., M. C. Marino, R. B. Johnston, Jr., J. Boyle, J. Curnutte, J. I. Gallin, H. L. Malech, S. M. Holland, H. Ochs, P. Quie, R. H. Buckley, C. B. Foster, S. J. Chanock, and H. Dickler. 2000. Chronic granulomatous disease. Report on a national registry of 368 patients. Medicine (Baltimore) 79:155-169.